Social welfare and adolescent vaccination programs in the united states: The economic opportunities for a systematic expansion

Social Work in Public Health

Volumn 24, Issue 5, 2009, Pages 414-445

  Vernon, John A ^a   Payette, Michael ^b   Chatterjee, Abhishek ^b  

^a IL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescent; Cost benefit; Cost effectiveness; Immunization; Vaccination

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INFLUENZA VACCINE; MENINGOCOCCAL CONJUGATE VACCINE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADOLESCENCE; COST-BENEFIT ANALYSIS; HEALTH EDUCATION; HEALTH POLICY; IMMUNIZATION; LITERATURE REVIEW; VACCINATION; WELFARE ECONOMICS;

ALLERGIC REACTION; CHICKENPOX; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEVER; HEADACHE; HEALTH CARE POLICY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; INFLUENZA; INJECTION SITE BURNING; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MEDICAL TECHNOLOGY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PERTUSSIS; PRACTICE GUIDELINE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SOCIAL WELFARE; TEMPERATURE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; SOCIAL WELFARE; UNITED STATES; VACCINATION;

NORTH AMERICA; UNITED STATES;

EID: 70449635996     PISSN: 19371918     EISSN: 1937190X     Source Type: Journal    
DOI: 10.1080/19371910903038165     Document Type: Review

References (92)

1. Antoñanzas, F., Garuz, R., Rovira, J., Antón, F., Trinxet, C., Navas, E., et al. (1995). Cost-effectiveness analysis of hepatitis vaccination strategies in Catlonia, Spain. Pharmaco Economics, 7(5), 428-443.
2. Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. American Economic Review, 53, 941-973.
3. Ball, R., Braun, M. M., Mootrey, G. T., & Vaccine Adverse Event Reporting System Working Group. (2001). Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clinical Infectious Diseases, 32, 1273-1280.
4. Banz, K., Wagenpfeil, S., Neiss, A., Goertz, A., Staginnus, U., Vollmar, J., et al. (2003). The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine, 21, 1256-1267.
5. Blake, D. R., Weber, B. M., & Fletcher, K. E. (2004). Adolescent and young adult women's misunderstanding of the term Pap smear. Archives of Pediatric Adolescent Medicine, 158, 966-970.
6. Bloom, B. S., Hillman, A. L., Fendrick, A. M., & Schwartz, J. S. (1993). A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Annals of Internal Medicine, 118(4), 298-306.
7. Brisson, M., & Edmunds, W. J. (2002). The cost-effectiveness of varicella vaccination in Canada. Vaccine, 20, 1113-1125.
8. Brisson, M., & Edmunds, W. J. (2003). Varicella vaccination in England and Wales: Cost-utility analysis. Archives of Disease in Childhood, 88, 862-869.
9. Britto, M. T., Atherton, H. D., & DeWitt, T. G. (2001). Immunizing adolescents in private practice: Lessons learned from hepatitis B. Preventative Medicine in Managed Care, 2(3), 127-134.
10. Caro, J. J., Getsios, D., El-Hadi, W., Payne, K., & O'Brien, J. A. (2005). Pertussis immunization of adolescents in the United States: An economic evaluation. Pediatric Infectious Disease Journal, 24(Suppl 5), S75-S82.
11. Centers for Disease Control and Prevention (CDC). (1991, November 22). Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of immunization practices advisory committee (ACIP). Morbidity and Mortality Weekley: Recommendations and Reports, 40, 1-19.
12. Centers for Disease Control and Prevention (CDC). (1998). Varicella vaccine information statement (VIS). Retrieved December 28, 2005, from http://www.cdc. gov/vaccines/pubs/vis/downloads/vis-varicella.pdf.
13. Centers for Disease Control and Prevention (CDC). (1999, October 1). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly: Recommendations and Reports, 48, 1-37.
14. Centers for Disease Control and Prevention (CDC). (2002). Pertussis fact sheet 2002. Retrieved December 27, 2005, from http://www.cdc.gov/nip/ publications/pink/pert.pdf
15. Centers for Disease Control and Prevention (CDC). (2005a). Adult and adolescent immunization program. Retrieved November 21, 2005, from http://www.cdc. gov/programs/immun01.htm.
16. Centers for Disease Control and Prevention (CDC). (2005b). Meningococcal vaccine information statement. Retrieved December 28, 2005, from www.cdc.gov/ vaccines/pubs/vis/downloads/vis-mening.pdf
17. Centers for Disease Control and Prevention (CDC). (2005c, January 7). Recommended childhood and adolescent immunization schedule-United States, 2005.Morbidity and Mortality Weekly: Recommendations and Reports, 53(51), Q1-Q3. Retrieved November 21, 2005, from http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5351-Immunizationa1.htm.
18. Centers for Disease Control and Prevention (CDC). (2005d). Viral hepatitis. Retrieved November 22, 2005, from http://www.cdc.gov/hepatitis/index. htm.
19. Centers for Disease Control and Prevention (CDC). (2006a, May 12). Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. Morbidity and Mortality Weekly, 55(18), 511-515. Retrieved July 23, 2009, from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5518a4.htm
20. Centers for Disease Control and Prevention (CDC). (2006b). Recommended childhood and adolescent immunization schedule-United States, 2006. Retrieved November 22, 2005, from http://www.cdc.gov/recs/schedules/down loads/child/2007/child-schedule-bw-print.pdf.
21. Centers for Disease Control and Prevention (CDC). (2006c). Inactivated influenza vaccine. Retrieved December 27, 2005, from http://www.cdc.gov/ vaccines/ pubs/vis/downloads/vis-flu.pdf.
22. Centers for Disease Control and Prevention (CDC). (2009a). Hepatitis A index: Overview and statistics. Retrieved July 23, 2009, from http://www.cdc.gov/ hepatitis/HAV/HAVfaq.htm#general
23. Centers for Disease Control and Prevention (CDC). (2009b). Hepatitis B index: Overview and statistics. Retrieved July 23, 2009, from http://www.cdc.gov/ hepatitis/HBV/HBVfaq.htm#overview
24. Centers for Disease Control and Prevention (CDC) 2009 Hepatitis C Index: Overview and Statistics. Retrieved July 23, 2009, from http://www.cdc.gov/ hepatitis/HCV/HCVfaq.htm#section1
25. Centers for Disease Control and Prevention (CDC). (2009c). Hepatitis Cindex: Overview and statistics. Retrieved July 23, 2009, from http://www.cdc.gov/ hepatitis/HCV/HCVfaq.htm#section1
26. Centers for Disease Control and Prevention (CDC). (2009d). 2009 child & adolescent immunization schedules. Retrieved July 23 2009, from http://www.cdc.gov/ vaccines/recs/schedules/child-schedule.htm
27. Centers for Disease Control and Prevention (CDC). (2009e). HPV vaccination. Retrieved July 23, 2009, from http://www.cdc.gov/vaccines/vpd-vac/ hpv/default. htm#vacc
28. Centers for Disease Control and Prevention (CDC). (2009f). Key facts about seasonal influenza (flu). Retrieved July 23, 2009, from http://www.cdc.gov/flu/keyfacts. htm
29. Clements, C. J., Abdool-Karimb, Q., Chang, M. L., Nkowanec, B., & Esparza J. (2004). Breaking new ground: Are changes in immunization services needed for the introduction of future HIV/AIDS vaccines and other new vaccines targeted at adolescents? Vaccine, 22(21-22), 2822-2826.
30. Cutler, D., McClellan, M., Newhouse, J., & Remler, D. Are medical prices declining? Quarterly Journal of Economics, 113(4), 991-1024.
31. De Wals, P., De Serres, G., & Niyonsenga, T. (2001). Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. Journal of the American Medical Association, 285, 177-181.
32. Edmunds, W. J., Brisson, M., Melegaro, A., & Gay, N. J. (2002). The potential costeffectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine, 20, 1316-1330.
33. Eisenberg, J. M. (1989). Clinical economics: A guide to the economic analysis of clinical practices. Journal of the American Medical Association, 262(20), 2879-2886.
34. Forns, X., Bukh, J., & Purcell, R. H. (2002). The challenge of developing a vaccine against hepatitis C virus. Journal of Hepatology, 37(5), 684-695.
35. Garuz, R., Torrea, J. L., Arnal, J. M., Forcen, T., Trinxet, C., Anton, F., et al. (1997). Vaccination against hepatitis B virus in Spain: A cost-effectiveness analysis. Vaccine, 15(15), 1652-1660.
36. Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., et al. (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Journal of the National Cancer Institute, 96(8), 604-615.
37. Gosling, H. (2000). European pharmacoeconomics: The fourth hurdle. Global Pharmaceutical Reports. New York: SMi Publishing.
38. Global Polio Eradication Initiative. (2005). Wild poliovirus weekly update. Retrieved November 28, 2005, from http://www.polioeradication.org/ casecount.asp.
39. Grace, J. A. (2006). Adolescent immunization: Challenges and opportunities. Journal of School Nursing, 22(2), 87-93.
40. Griffiss, J. M., Brandt, B. L., & Bround, D. D. (1982). Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infection and Immunity, 37, 205-208.
41. Groft, J. N., Hagen, B., Miller, N. K., Cooper, N., & Brown, S. (2005). Adolescent health: A rural community's approach. Rural and Remote Health, 5, 366.
42. Hanslik, T., Boëlle, P. Y., Schwarzinger, M., Carrat, F., Freedberg, K. A., Valleron, A. J., et al. (2003). Varicella in French adolescents and adults: Individual risk assessment and cost-effectiveness of routine vaccination. Vaccine, 21, 3614-3622.
43. Harris, A., Yong, K., & Kermode, M. (2001). An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib- HepB): A decision analytic approach to cost-effectiveness. Australian and New Zealand Journal of Psublic Health, 25(3), 222-229.
44. Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000). Willingness to pay for a quality-adjusted life year: In search of a standard. Medical Decision Making, 20(3), 332-342.
45. Inchauspe, G., & Feinstone, S. (2003). Development of a hepatitis C virus vaccine. Clinics in Liver Disease, 7(1), 243-259.
46. Iskedjian, M., Walker, J. H., & Hemels, M. E. H. (2004). Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine, 22, 4215-4227.
47. Jacobs, J., Margolis, H. S., & Coleman, P. J. (2000). The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Archives in Pediatric and Adolescent Medicine, 154, 763-770.
48. Jacobs, J., Saab, S., & Myerhoff, A. S. (2003). The cost-effectiveness of hepatitis immunization for U.S. college students. Journal of American College Health, 51(6), 227-236.
49. Jacobson, V. J., & Szilagyi, P. (2005). Patient reminder and patient recall systems to improve immunization rates. Cochrane Database of Systematic Reviews, 3, CD003941.
50. Jommi, C. (2001). Pharmaceutical policy and organization of the regulatory authorities in the main EU countries. (Collana Cergas, Centro di ricerche sullagestione dell'assistenza sanitaria dell'Università Bocconi). Milan, Italy: CERGAS, Egea Publishing.
51. Klein, J. D., Allan,M. J., Elster, A. B., Stevens,D., Cox, C., Hedberg, V. A., et al. (2001). Improving adolescent preventive care in community health centers. Pediatrics, 107, 318-327.
52. Krahn, M., Guasparini, R., Sherman, M., & Detsky, A. S. (1998). Costs and costeffectiveness of a universal, school-based hepatitis B vaccination program. American Journal of Public Health, 88(11), 1638-1644.
53. Krahn, M. D., John-Baptiste, A., Yi, Q., Doria, A., Remis, R. S., Ritvo, P., et al. (2005). Potential cost-effectiveness of a preventative hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine, 23, 1549-1558.
54. Lee, G. M., Lebaron, C., Murphy, T. V., Lett, S., Schauer, S., & Lieu, T. A. (2005). Pertussis in adolescents and adults: Should we vaccinate? Pediatrics, 115, 1675-1684.
55. Margolis, H. S., Coleman, P. J., Brown, R. E., Mast, E. E., Sheingold, S. H., & Arevalo, J. A. (1995). Prevention of hepatitis B virus transmission by immunization: An economic analysis of current recommendations. Journal of the American Medical Association, 275(15), 1201-1208.
56. Mayo Clinic. (2004). Your child's physical: What to know before you go. Retrieved November 28, 2005, from http://www.mayoclinic.com/health/childrens- health/ FL00002.
57. Merck ,(2006). Gardasil prescribing information. Retrieved July 23, 2009, from http://www.merck.com/product/usa/picirculars/g/gardasil/gardasil-pi.pdf.
58. Morrow, T. (2006). Remarkable work went into designing the new HPV vaccine. Managed Care, 15(9), 70-71.
59. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsagué, X., Shah, K. V., et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348, 518-527. (Pubitemid 36159887)
60. Murphy, K. M., & Topel, R. H. (2003). Measuring the gains from medical research: An economic approach. Chicago: University of Chicago Press.
61. National Cancer Institute. (2005). Vaccine protects against virus linked to half of all cervical cancers. Retrieved January 10, 2006, from http://www.cancer.gov/ clinicaltrials/results/cervical-cancer-vaccine1102.
62. National Committee for Quality Assurance. (2001). Adolescent immunization status. Retrieved November 29, 2005, from http://www.ncqa.org/somc2001/ADOL- IMM/SOMC-2001-AIS.htm.
63. National Foundation for Infectious Diseases. (2005). Pertussis disease fact sheet. Retrieved July 23, 2009, from http://www.nfid.org/-old/factsheets/ pertussis.pdf
64. Purdy, K. W., Hay, J.W., Botteman, M. F., &Ward, J. I. (2004). Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: A cost-benefit analysis. Clinical Infections Diseases, 39, 20-28.
65. Rosenstein, N. E., Levine, O., Taylor, J. P., Evans, D., Plikaytis, B. D., Wenger, J. D., et al. (1998). Efficacy of meningococcal vaccine and barriers to vaccination. Journal of American Medical Association, 279, 435-439.
66. Rupp, R., Rosenthal, S. L., & Middleman, A. B. (2006). An opportunity to enhance early adolescent preventative services. Journal of Adolescent Health, 39(4), 461-464.
67. Rupp, R., Stanberry, L. R., & Rosenthal, S. L. (2004). New biomedical approaches for sexually transmitted infection prevention vaccines and microbicides. Adolescent Medical Clinics, 15, 393-407.
68. Sanders, G. D., & Taira, A. V. (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases, 9(1), 37-48.
69. Scott, R. D., Meltzer, M. I., Erickson, L. J., De Wals, P., & Rosenstein, N. E. (2002). Vaccinating first-year college students living in dormitories for meningococcal disease. American Journal of Preventative Medicine, 23(2), 98-105.
70. Scuffham, P. A., Lowin, A. V., & Burgess, M. A. (2000). The cost-effectiveness of varicella vaccine programs for Australia. Vaccine, 18, 407-415.
71. Shepard, C. W., Ortega-Sanchez, I. R., Scott, R. D., 2nd, Rosenstein, N. E., & ABCs Team. (2005). Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics, 115(5), 1220-1232.
72. Skull, S. A., Butler, J. R., Robinson, P., & Carnie, J. (2001). Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. International Journal of Epidemiology, 30, 571-578.
73. Sloan, F. (1995). Valuing Health Care (2nd ed). Cambridge: Cambridge University Press.
74. Szucs, T., Smala, A., Berger, K., & Windorfer, A. (1998). Economic evaluation of different vaccination strategies against hepatitis B for children and adolescents [in German]. Medizinische Klinik, 93, 468-477.
75. Thiry, N., Beutels, P., Tancredi, F., Romanò, L., Zanetti, A., Bonanni, P., et al. (2004). An economic evaluation of varicella vaccination in Italian adolescents. Vaccine, 22, 3546-3562.
76. Thomas, L. (1975). The lives of a cell. New York: Bantam Books.
77. Trotter, C. L., & Edmunds, W. J. (2002). Modeling cost-effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. British Medical Journal, 324, 1-6.
78. Van Damme, P., Tormans, G., Beutels, P., & Van Doorslaer, E. (1995). Hepatitis B prevention in Europe: A preliminary economic evaluation. Vaccine, 13, S54-S57.
79. Van Rie, A., & Hethcote, H. W. (2004, August 13). Adolescent and adult pertussis vaccination: Computer simulations of five new strategies. Vaccine, 22(23-24), 3154-3165.
80. Walboomers, J., Jacobs, M., Manos, M., Bosch, F. X., Kummer, J. A., Shah, K. V., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 189, 12-19.
81. Washington Department of Health. (2005). Vaccines for children (VFC) program eligibility. Retrieved July 23, 2009, from http://www.doh.wa.gov/cfh/ Immunize/ providers/vfc-eligibility.htm
82. Weinstein, M. C., & Stason, W. B. (1977). Foundations of cost-effectiveness analysis for health and medical practice. New England Journal of Medicine, 296, 716-721.
83. Weisbrod, B. (1991). The healthcare quadrilemma: An essay on technological change, insurance, quality of care, and cost containment. Journal of Economic Literature, XXIX, 523-553.
84. Weycker, D., Edelsberg, J., Halloran, M. E., Longini, I. M., Jr., Nizam, A., Ciuryla, V., et al. (2005). Population-wide benefits of routine vaccination of children against influenza. Vaccine, 23, 1284-1293.
85. Widdice, L. E., & Kahn, J. A. (2006). Using the new HPV vaccines in clinical practice. Cleveland Clinic Journal of Medicine, 73(10), 929-935.
86. Wiebe, T., Fergusson, P. Horne, D., Shanahan, M., Macdonald, A., Heise, L., et al. (1997). Hepatitis B immunization in a low-incidence province of Canada: Comparing alternative strategies. Medical Decision Making, 17(4), 472-482.
87. World Health Organization. (2003). Varicella. Retrieved December 28, 2005, from http://www.who.int/vaccines/en/varicella.shtml.
88. World Health Organization. (2005a). Neonatal tetanus. Retrieved December 28, 2005, from http://www.who.int/immunization-monitoring/diseases/neonatal- tetanus/en/index.html.
89. World Health Organization. (2005b). Vaccine history. Retrieved December 28, 2005, from http://www.who.int/vaccines-diseases/history/history.shtml.
90. World Watch Institute. (1999). Eradicating polio: A model for international cooperation. Retrieved November 21, 2005, from http://www.worldwatch.org/press/ news/1999/01/25/.
91. Zhou, F., Santoli, J., Messonnier, M. L., Yusuf, H. R., Shefer, A., Chu, S. Y., et al. (2005). Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Archives of Pediatric and Adolescent Medicine, 159, 1136-1144.
92. Zurn, P., & Danthine, J. P. (1998). Economic evaluation of different vaccination strategies against hepatitis B in Switzerland [in German]. Sozial- und Praventivmedizin, 1, S61-S64.